Wealth Fund Had Invested in Series B for Emerging Pharma Company
Posted on 08/28/2016
Sovereign wealth funds continue to play a key part in the aggregate investor composition in emerging pharmaceutical companies in the United States, especially in the areas of cancer therapies and combating neurodegenerative diseases. South San Francisco-based Denali Therapeutics Inc. raised US$ 130 million in a Series B round of preferred equity financing in June 2016. […]
- Alaska Permanent Fund Corporation
- Alternatives
- ARCH Venture Partners
- Denali Therapeutics
- pharmaceutical
- Venture Capital